HPS Pharmacies wish to advise that Phebra has changed the labelling of Magnesium Sulfate Heptahydrate 50% Concentrated Injection as follows:

Magnesium Sulfate Heptahydrate 50% Concentrated Injection  Magnesium sulfate heptahydrate 500mg/mLARTG 160885 

The vial and carton labelling has been updated following a recommendation from the Therapeutic Goods Administration (TGA). The new labelling gives the mmol strength more prominence to align with current clinical practice.

Each 10mL vial of Magnesium Sulfate Heptahydrate 50% Concentrated Injection contains 5g of magnesium sulfate heptahydrate, which is equivalent to 20mmol of magnesium ions.

To ensure uninterrupted supply, Phebra will continue to supply product from the current batch (batch number 14955) which only expresses the mmol strength within the content on the main panel. Future batches will have the mmol strength displayed more prominently adjacent to the medicine name.

For further information, consult the updated Product Information.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Phebra on 1800 720 020 or your pharmacist at HPS Pharmacies.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates